|Last Price||Today's Change||52-Week Range||Trading Volume|
|60.90||-1.51 (-2.42%)||52.06 - 71.60||1.9 million|
Market data as of 10:16AM 09/01/15. Quotes are delayed by at least 15 min.
U.S. Food and Drug Administration Accepts for Priority Review the Biologics License Application for Empliciti (elotuzumab) for the Treatment of Multiple Myeloma in Patients Who Have Received One or More Prior Therapies
09/01/2015 7:30 AM ET